This week saw more safety questions emerge with COVID vaccines. Blood clots have been seen with the Astra vaccine and now with the J&J vaccine, prompting the FDA to call for a pause in its roll-out. These serious clots appear to be a one-in-a-million risk and likely aren’t a deal breaker for use in certain patient populations. Meanwhile more progress has been made on COVID-19 treatments, with antibody products from Regeneron, Lilly and GSK showing a 70-80% reduction in risk of hospitalisation. The combination of effective vaccines and therapeutics should now lead to a dramatic reduction in COVID-related deaths in those countries with good access to both.